ORIC Pharmaceuticals is an American clinical-stage biopharmaceutical developer. The company mainly develops new treatments for tumor cell drug resistance and provides treatment options for patients with relapsed cancer. Although rapidly developing targeted therapy technologies have substantially improved patient outcomes, cancers often become resistant to chemotherapy drugs, and relapsed patients often lack further treatment options. Recently, ORIC Pharmaceuticals announced the sale of 5,376,344 shares of its common stock to Pfizer at a price of $4.65 per share for a proceeds of approximately $25 million.
This article is transferred from: https://www.itjuzi.com/investevent/13740079
This site is only for collection, and the copyright belongs to the original author.